NVDA
NVIDIA
-- 138.850 TSLA
Tesla
-- 355.840 BABA
Alibaba
-- 124.730 INTC
Intel
-- 23.600 PLTR
Palantir
-- 119.160 
NEWS
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. (NYSE: ANVS) has announced promising early research results for its lead drug, buntanetap, in combination with other approved drugs for Alzheimer's disease (AD) treatment. While recent FDA-approved drugs like Leqembi and Kisunla may slow cognitive decline in AD patients, they do not improve cognition. Similarly, GLP-1 drugs, originally developed for type 2 diabetes and obesity, have shown potential in AD treatment but do not enhance cognitive functions.
Annovis Bio's innovative approach aims to address this critical gap in AD treatment. The company's research suggests potential future breakthroughs in improving cognition for AD patients, a significant target for millions suffering from this progressive disease. This development positions Annovis Bio as a notable player in the pharmaceutical industry's efforts to transform Alzheimer's treatment.
Annovis Bio's innovative approach aims to address this critical gap in AD treatment. The company's research suggests potential future breakthroughs in improving cognition for AD patients, a significant target for millions suffering from this progressive disease. This development positions Annovis Bio as a notable player in the pharmaceutical industry's efforts to transform Alzheimer's treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8170
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call